Subsequently, several oral KRASG12C inhibitors were optimized and introduced.86 The approval of Lumakras, an Amgen-developed drug, in May 2021 for treating NSCLC patients with KRASG12C mutations marks a significant milestone in KRAS-targeting drug discovery.53 However, the rapid emergence of adaptive resistance and reactivation of MAPK signaling following treatment necessitates the development of KRAS-targeted drugs utilizing TPD technologies, such as PROTACs.484. This evidence concerns the gene KRAS and non-small cell lung carcinoma.